Success Metrics

Active Trials
1(33%)

Phase Distribution

Ph phase_2
2
67%
Ph phase_1
1
33%

Phase Distribution

1

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 2Efficacy & side effects
2(66.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 2 finished

Non-Completion Rate

100.0%

2 ended early

Currently Active

1

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Terminated(2)

Detailed Status

Withdrawn2
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
1
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Phase 11 (33.3%)
Phase 22 (66.7%)

Trials by Status

recruiting133%
withdrawn267%

Recent Activity

1 active trials
Showing 3 of 3
recruitingphase_2

A Study to Assess TTI-0102 vs Placebo in MELAS Patients

NCT06644534
withdrawnphase_2

Study of Cysteamine-pantetheine Disulfide (TTI-0102) in Mild to Moderate COVID-19

NCT05212662
withdrawnphase_1

TTI-0102 for Veterans With TBI

NCT04262895

Clinical Trials (3)

Showing 3 of 3 trials
NCT06644534Phase 2

A Study to Assess TTI-0102 vs Placebo in MELAS Patients

Recruiting
NCT05212662Phase 2

Study of Cysteamine-pantetheine Disulfide (TTI-0102) in Mild to Moderate COVID-19

Withdrawn
NCT04262895Phase 1

TTI-0102 for Veterans With TBI

Withdrawn

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3